ArticleDiscover oncology2025
Exploration of the current status and trends of pancreatic cancer immune cells in the past 30 years: a bibliometric analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveImmune cells are pivotal in progressing and treating pancreatic cancer. Over the past three decades, the complex interactions between pancreatic cancer and immune cells have garnered much attention, as evidenced by the increasing number of publications in this domain. This bibliometric study maps the global research landscape of pancreatic cancer immune cell interactions, emphasizing evolving trends, collaborative networks, and therapeutic innovation.
methodUsing VOSviewer and CiteSpace, we analyzed 2658 articles from the Web of Science Core Collection (2000-2024) to evaluate publication trends, collaborative networks, keyword dynamics, and highly cited works.
resultsAnnual publications surged from 4 (2000) to 453 (2024), with China (44.9%) and the U.S. (33.6%) dominating output. Key institutions included Fudan University (102 articles) and Zhejiang University (88 articles). Keyword evolution revealed three phases: antitumor mechanisms, clinical translation of checkpoint inhibitors, and recent emphasis on stromal-immune crosstalk. High-impact works by Brahmer (N Engl J Med 366:2455-2465, 2012) and Marabelle (J Clin Oncol 38:1-10, 2020) underscored immunotherapy milestones.
conclusionThis bibliometric analysis highlights the dynamic nature of pancreatic cancer immune cell research, emphasizing the growing global interest and investment in this field. The findings underscore the need for ongoing monitoring of research trends to inform and propel innovative therapeutic strategies, ultimately improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.